Purple Biotech (PPBT) Competitors $2.27 +0.05 (+2.25%) Closing price 03:59 PM EasternExtended Trading$2.26 -0.01 (-0.26%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. CING, ELEV, AYTU, BCAB, ADAP, MBRX, CASI, QTTB, FNCH, and PASGShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Cingulate (CING), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), Adaptimmune Therapeutics (ADAP), Moleculin Biotech (MBRX), CASI Pharmaceuticals (CASI), Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors Cingulate Elevation Oncology Aytu BioPharma BioAtla Adaptimmune Therapeutics Moleculin Biotech CASI Pharmaceuticals Q32 Bio Finch Therapeutics Group Passage Bio Cingulate (NASDAQ:CING) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation. Does the media prefer CING or PPBT? In the previous week, Cingulate had 15 more articles in the media than Purple Biotech. MarketBeat recorded 15 mentions for Cingulate and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 beat Cingulate's score of -0.07 indicating that Purple Biotech is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Neutral Purple Biotech Neutral Do insiders and institutionals believe in CING or PPBT? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, CING or PPBT? Purple Biotech is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$4.10-0.97Purple BiotechN/AN/A-$7.24M-$0.42-5.40 Is CING or PPBT more profitable? Purple Biotech's return on equity of -14.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -232.16% -132.07% Purple Biotech N/A -14.00%-12.52% Which has more risk and volatility, CING or PPBT? Cingulate has a beta of -0.74, indicating that its share price is 174% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Do analysts recommend CING or PPBT? Cingulate presently has a consensus target price of $26.00, indicating a potential upside of 551.63%. Purple Biotech has a consensus target price of $33.00, indicating a potential upside of 1,353.74%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPurple Biotech beats Cingulate on 7 of the 11 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.74M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-5.4020.4330.4625.16Price / SalesN/A238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book0.187.918.956.21Net Income-$7.24M-$54.72M$3.26B$265.38M7 Day Performance-1.73%1.66%1.06%-1.13%1 Month Performance-18.35%5.88%4.31%-0.71%1 Year PerformanceN/A8.72%28.39%18.86% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech1.5075 of 5 stars$2.27+2.3%$33.00+1,353.7%N/A$5.74MN/A-5.4020Gap DownCINGCingulate2.484 of 5 stars$4.05-2.9%$26.00+542.0%-70.8%$21.95MN/A-0.4820Earnings ReportShort Interest ↑ELEVElevation Oncology1.4002 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540AYTUAytu BioPharma3.6331 of 5 stars$2.24-5.5%$10.00+346.4%-21.8%$21.27M$81M-3.11160Positive NewsBCABBioAtla2.3097 of 5 stars$0.36+2.8%$5.00+1,279.3%-80.1%$20.60M$11M-0.3360ADAPAdaptimmune Therapeutics2.1171 of 5 stars$0.09+10.7%$1.35+1,475.4%-94.6%$20.54M$178.03M-0.32490Insider TradeAnalyst RevisionGap DownMBRXMoleculin Biotech3.027 of 5 stars$0.62-7.8%$4.00+543.1%-78.2%$20.38MN/A0.0020CASICASI Pharmaceuticals3.6835 of 5 stars$1.73+6.1%$4.00+131.2%-64.2%$20.05M$28.54M-0.68180Upcoming EarningsQTTBQ32 Bio2.6042 of 5 stars$1.79+9.8%$12.17+579.7%-95.3%$19.88M$1.16M-0.4239News CoverageShort Interest ↓Gap DownFNCHFinch Therapeutics GroupN/A$12.24-1.6%N/A+8.2%$19.66MN/A-1.39190PASGPassage Bio3.8489 of 5 stars$5.90-5.9%$150.00+2,442.4%-47.3%$19.56MN/A-0.29130 Related Companies and Tools Related Companies Cingulate Competitors Elevation Oncology Competitors Aytu BioPharma Competitors BioAtla Competitors Adaptimmune Therapeutics Competitors Moleculin Biotech Competitors CASI Pharmaceuticals Competitors Q32 Bio Competitors Finch Therapeutics Group Competitors Passage Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access